Gravitas Life Sciences, LLC was acquired by Hepion Pharmaceuticals, Inc. on October 6, 2026, according to the Form 8-K Hepion Pharmaceuticals, Inc. filed with the SEC. The filing states a price of $2.3 million. It is the only completed acquisition Hepion Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months (Form 8-K, October 9, 2026).
Hepion Pharmaceuticals, Inc. agreed to acquire Gravitas Life Sciences, LLC on Oct 9. 1 companies announced an acquisition this week.
Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.
| Bowman Consulting Group Ltd. | agreed to be acquired by Prive Parent, Inc. |
Competing with, selling to or investing in Hepion Pharmaceuticals, Inc. after this deal? See the free Snapshot first.
Free to see. No signup.
Hepion Pharmaceuticals, Inc. completed its acquisition of Gravitas Life Sciences, LLC on 2026-10-06, according to the Form 8-K Hepion Pharmaceuticals, Inc. filed with the SEC on 2026-10-09. The filing states a price of $2.3 million.
| Acquirer | Hepion Pharmaceuticals, Inc. |
|---|---|
| Acquired | Gravitas Life Sciences, LLC |
| Completed | 2026-10-06 |
| Price stated in the filing | $2.3 million |
| Reported by | Hepion Pharmaceuticals, Inc. (HEPA), the buyer |
| Filing | Form 8-K, filed 2026-10-09 |
Want the whole picture on Hepion Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Hepion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hepion Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On October 6, 2026, the Company completed the acquisition of all of the issued and outstanding membership interests of GLS from the Sole Member pursuant to the Purchase Agreement.
How much did Hepion Pharmaceuticals, Inc. pay for Gravitas Life Sciences, LLC?
Pursuant to the Purchase Agreement, at the closing of the transactions which occurred on October 6, 2026 (the "Closing"), the Sole Member sold the Purchased Securities to the Company in exchange for the right to receive from the Company (i) $2,000,000 in cash and (ii) 25,000,000 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), which was equal to $2,250,000 divided by the Buyer Closing Stock Price (as defined in the Purchase Agreement) (the "Stock Consideration" and, together with the cash consideration, the "Purchase Consideration").
More from the filing
As a result of the Closing, GLS became a wholly owned subsidiary of the Company.
Business of GLS GLS is a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation.
On November 3, 2023, GLS entered into a patent license agreement (the "Avior License Agreement") with Avior Inc. d/b/a Avior Bio, LLC ("Avior").
Quoted from Hepion Pharmaceuticals, Inc.'s Form 8-K.
This is the only completed acquisition Hepion Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Hepion Pharmaceuticals, Inc.'s funding history
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Hepion Pharmaceuticals, Inc.Look up Hepion Pharmaceuticals, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Hepion Pharmaceuticals, Inc.Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.